Charcot Marie Tooth Disease
Conditions
Brief summary
Charcot Marie Tooth Disease is a family of inherited peripheral neuropathies, with over 70 causative genes identified to date.1-4 Muscle cramps are frequent in CMT, affecting up to 85% of patients with some subtypes of CMT. These cramps impact quality of life and have been identified as an important therapeutic target for clinical trials in CMT.1-4 There is no FDA approved treatment for muscle cramps.5 Mexiletine is a sodium channel blocker approved for treatment of arrhythmias. As a sodium channel blocker, mexiletine offers the promise of effective therapy for muscle cramps.
Detailed description
This study will provide data on the short term efficacy of oral mexiletine in helping to prevent muscle cramps in adults with CMT. The study will also assess the short-term safety and tolerability of low dose mexiletine in adults with CMT.
Interventions
OTHERPlacebo
240 mg lactose powder in a size 3 capsule taken by mouth 3 times daily for 5-7 days
DRUGMexiletine
150 mg Mexiletine taken by mouth in capsule form 3 times daily for 5-7 days
Sponsors
University of Rochester
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The subject has known CMT, previously diagnosed by a neurologist with subspeciality expertise in neuromuscular disorders/peripheral neuropathy. The diagnosis of CMT relies on a combination of clinical history (including family history), neurological examination electrophysiological features, and prior genetic testing results. * The subject is at least 18 years old, and has signed the Informed Consent Form. * The subject is ambulatory (cane, walker, orthoses allowed). * The subject has experienced muscle cramps and has known provokable hamstring or calf muscle cramps on MVC. * The subject has a reliable method of birth control (if a female subject of child bearing potential). Reliable birth control is defined as Hormonal contraception Intrauterine contraception/device Any two barrier methods (combination of male or female condom with diaphragm sponge or cervical cap) together with spermicidal foam/gel/film/cream/suppository True abstinence
Exclusion criteria
* The subject has a known neuropathy from another source (e.g., diabetes, drug induced, alcohol, etc.). * The subject has an untreated medical disorder known to predispose to muscle cramps * The subject is pregnant or nursing, has a known mexiletine allergy or has taken mexiletine in the past 12 weeks. * The subject is participating in another therapeutic trial. * The subject has second or 3rd degree heart block, atrial flutter/fibrillation, ventricular arrhythmias, or is receiving treatment of a cardiac arrhythmia. * The subject is currently taking another agent for muscle cramps or a muscle relaxant (e.g., benzodiazepine, baclofen, tizanidine, soma, meprobromate). * The subject is on another sodium channel blocker or medication that precludes administration of mexiletine. * The subject has known diabetes mellitus, liver or kidney disease requiring ongoing treatment, untreated thyroid dysfunction, symptomatic cardiomyopathy, or symptomatic coronary artery disease. * The subject, in the opinion of the investigator, is unsuitable for enrollment for any other reason
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With a Decrease in Cramp Duration | 120 minutes | Participant will be evaluated for muscle cramps 120 minutes following a single dose of oral mexiletine. The Clinical Evaluator applied pressure to provoke hamstring cramps bilaterally, one at a time 2 hours after dose. The cramp duration in seconds of the right hamstring was used. |
| Number of Participants With a Decrease in Cramp Intensity | 120 minutes | Participant will be evaluated for muscle cramps 120 minutes following a single dose of oral mexiletine. The Clinical Evaluator applied pressure to provoke hamstring cramps bilaterally, one at a time 2 hours after dose. The cramp intensity of the right hamstring was reported by the subject on a scale of 1-10 with 1 being weak and 10 being severe. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| All Participants | 4 |
| Total | 4 |
Baseline characteristics
| Characteristic | All Participants |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 1 Participants |
| Age, Categorical Between 18 and 65 years | 3 Participants |
| Region of Enrollment United States | 4 Participants |
| Sex: Female, Male Female | 2 Participants |
| Sex: Female, Male Male | 2 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 4 | 0 / 4 |
| other Total, other adverse events | 0 / 4 | 0 / 4 |
| serious Total, serious adverse events | 0 / 4 | 0 / 4 |
Outcome results
Primary
Number of Participants With a Decrease in Cramp Duration
Participant will be evaluated for muscle cramps 120 minutes following a single dose of oral mexiletine. The Clinical Evaluator applied pressure to provoke hamstring cramps bilaterally, one at a time 2 hours after dose. The cramp duration in seconds of the right hamstring was used.
Time frame: 120 minutes
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Mexiletine | Number of Participants With a Decrease in Cramp Duration | 2 participants |
| Placebo | Number of Participants With a Decrease in Cramp Duration | 0 participants |
Primary
Number of Participants With a Decrease in Cramp Intensity
Participant will be evaluated for muscle cramps 120 minutes following a single dose of oral mexiletine. The Clinical Evaluator applied pressure to provoke hamstring cramps bilaterally, one at a time 2 hours after dose. The cramp intensity of the right hamstring was reported by the subject on a scale of 1-10 with 1 being weak and 10 being severe.
Time frame: 120 minutes
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Mexiletine | Number of Participants With a Decrease in Cramp Intensity | 1 participants |
| Placebo | Number of Participants With a Decrease in Cramp Intensity | 2 participants |